Table of Contents
Gcmaf is a vitamin D-binding protein. It’s scientifically referred to as Gc protein-derived macrophage triggering element. It’s a protein that supports the immune system, and naturally discovered in the body. Gcmaf activates macrophage cells, or the cells responsible for battling infection and disease. (1 )
The two newest publications on gcmaf help reinterpreting the biological and scientific results separately observed in vitro and in vivo by a number of scientists. The hypothesis that chondroitin sulfate might be responsible for the results thus far attributed to gcmaf, solves al the disparities and contradictions that have characterized this field of immunotherapy. Moreover, this hypothesis lays the foundation for the advancement of non-proteinic macrophage activating aspects that are not extracted from human blood, thus avoiding all the risks associated with human blood-derived items. (2 ).
A 1997 study checked gcmaf on mice with cancer. It discovered that gcmaf enhanced their survival from 16 days to 32 days.
A few years later on, the researchers evaluated the treatment on individuals with breast, colorectal, and prostate cancers. They provided shots of a small amount of gcmaf once a week. After a couple of months, all of the clients were cured, according to the research studies. 4 to 7 years later, their cancers had not come back.
These outcomes sound impressive, however there were some huge problems with the studies. For something, they were extremely small– simply eight to 16 individuals each. Everybody in the studies had actually currently been on standard cancer treatments like surgical treatment, chemotherapy, or radiation. So it was tough to tell whether these treatments, or gcmaf, triggered the cancers to diminish.
Likewise, medical professionals usually utilize imaging and lab tests to phase cancers– to put it simply, to see how big the cancer is and whether it has actually spread out. The researchers didn’t do this. Instead, they took blood tests to examine nagalase levels, which isn’t a tested way to check for cancer or to see if it has actually gotten smaller sized.
Finally, the scientists never ever evaluated whether gcmaf in fact activated macrophages in the clients’ blood. So they couldn’t make certain that the treatment was operating at all.
Three doctors from the Anticancer Fund, a nonprofit group that promotes cancer research study, published a letter in 2014 that described many of the worry about the studies. They discovered numerous mistakes in the research studies’ claims and said that its conclusions “make no sense.”.
Future of gcmaf
A few scientists are still investigating gcmaf as a possible cancer treatment. Some early research studies suggest that it might be practical for people with late-stage cancers. It’s tough to understand whether gcmaf works. The research studies that have actually been done so far took a look at very small numbers of people. A few of them consisted of only one person. Larger studies are needed to show that this treatment deals with cancer which it’s safe.
Macrophages may still hold promise. Scientists are trying to learn whether monoclonal antibodies or other drugs might help macrophages eliminate cancer cells.
Till we know more, physicians stick to other immunotherapies, like checkpoint inhibitors, that have more proof behind them. If you have questions about gcmaf or any other cancer treatment you’ve checked out online, your cancer doctor is the very best individual to answer them. (3 ).
Diseases for GcMAF Therapy
GcMAF macrophage activation therapy works in the treatment of numerous illness, such as cancer, HIV AIDS, Hepatitis B virus (HBV), Hepatitis C infection (HCV), Herpes Simplex virus (HSV), Tuberculosis, Pneumonia infection, Epstein-Barr virus (EBV), cystitis/urinary system infection (UTI), Endometriosis, Selective iga deficiency disorder and influenza virus.
In healthy individuals the immune system might have the ability to conquer numerous sort of diseases, however individuals with a jeopardized immune system will take advantage of gcmaf treatment.
In the great bulk of individuals there are no side-effects with our 2nd generation GcMAF treatment, or side-effects are really small and very uncommon. Low grade fever and eczema has actually been observed in about 1 out of 100 clients using gcmaf but these were short-term effects.
Treatment in our center has actually been by Intramuscular (IM), Subcutaneous (SC) and Intramural (IT) injection.
In Combination With Other Treatments gcmaf can be securely utilized with a wide range of other basic treatments and drugs to improve their result. We refer to this as integrative medicine.
A mix with anti-cancer drugs and radiation therapy (radiotherapy) is possible. For optimal impact and gain from gcmaf, administer a couple of days apart from chemotherapy. Radiation therapy does not have significant results on GcMAF, so both can be used together at any time. In our scientific experience we have actually observed substantial cancer killing results from gcmaf combined with palliative radiotherapy in patients who underwent substantial previous chemotherapy treatment.
Studies show that gcmaf has anti-angiogenic activity in addition to growth killing activity through the activation of macrophages.
Gcmaf can be integrated with Sonodynamic Treatment (SDT), Photodynamic Therapy (PDT) or both (Sonophotodynamic Treatment, SPDT), Maitake Extract, Coley Vaccine (Coley Fluid), high-dose IV Vitamin C, low dosage Naltrexone (LDN), Alpha-Lipoic Acid, hyperthermia therapy, immunotherapies and cancer vaccines (such as autologous cancer vaccine).
Gcmaf needs to be utilized in mix with a minimum of 5,000 IU vitamin D3 daily. Blood levels of vitamin D are frequently low in numerous illness such as cancer, HIV HELP, and so on. Normal vitamin D levels are needed for gcmaf to work fully. Have your blood 25 hydroxy-vitamin D and calcium levels tested. If blood calcium levels become raised, vitamin D3 doses might need to be decreased to achieve an optimal balance.
Mixes to Avoid GcMAF can be safely used with a wide array of drugs and other treatments. Nevertheless, we advise:.
Very little use of steroids is desirable because of their immune suppressing effect, nevertheless steroids may be securely utilized with gcmaf if required and recommended by your doctor.
Radiation therapy is preferred over chemotherapy whenever possible.
Treatment is by intramuscular (IM) or subcutaneous (SC) injection of the gcmaf macrophage triggering factor, 1-2 times each week (or as recommended by the dealing with physician).
Treatment in our center has likewise been by intramural (IT) injection although IM and SC injections are by far the most typical technique of administration.
Excellent aseptic handling with ethanol is needed when utilizing the vials. (4 ).
How does GcMAF work?
Gcmaf is a glycoprotein that activates macrophages which in turn increases macrophage activity and changes them into Natural Killer (NK) cells.
Gcmaf has been medically shown to be mainly free of any serious adverse effects. Only flu-like signs in couple of portion of those who get the injection. (5 ).
To be more specific:
In a healthy individual macrophages in our bloodstream search our bodies and kill malignancies; they get the message to go on the attack from Gc MAF, which is converted from Gc Protein. However deadly cells like cancer send an enzyme called Nagalase that stops conversion of Gc protein to Gc MAF (Macrophage Activating Factor); so the macrophages never ever get the message to go into action in this way cancer suppresses the immune system, and cancer cells grow uncontrolled.
To reverse this we draw out Gc Protein from blood; modify it outside the body to end up being the missing out on GcMAF, and inject it when a week for 25 weeks for early cancers, 50 or more weeks for late stage cancers. (Encapsulated tumours require extra treatment.) HIV can require as little as 16 weeks.
In its function of body immune system regulator, gcmaf reverses other diseases that attack the immune system like Osteoporosis, Aids, Hodgkins, Lupus, MS, Fibromyalgia, Parkinsons, numerous bacterial and viral infections and various types of Immune dysfunction.
Small pre-clinical trials to construct the case are again happening.
Those diagnosed with any of these illnesses or who are otherwise convinced of the advantages of gcmaf for their health and who have done their own research study on it are invited to react. We ask for a copy of diagnostic details and upgrade reports from a doctor during and after treatments, to help construct the case that gcmaf is a treatment for various health problems, which will help to make it offered to the public. Participants are free to stop at any time. (6 ).
A very appropriate GcMAF history
Gcmaf first sprang to internet notoriety in 2015, with an alternate health and conspiracy publication, Natural News, claiming the following.
A specific cure named gcmaf (short for “Gc protein-derived macrophage activating element,” which is a chemically altered type of a natural protein that supposedly promotes the activity of a specific type of white blood cell) “has the possible to be a universal remedy for cancer”.
It didn’t take wish for gcmaf to attain messianic status on the planet of online hocus pocus and make-believe medical treatments. Natural News continued in the very same article;
” [gcmaf] is likewise thought,” the web site reported, “to be capable of treating and reversing autism, HIV, liver/kidney illness and diabetes.” Rumor has it that gcmaf has the possible to be a cure for much more diseases, such as herpes, as well.”.
Regardless of the numerous research articles released in trusted medical journals (most now withdrawed) claiming to validate gcmaf as effective in the treatment of cancers, gcmaf does not treat cancer, or for that matter, any other ailment. It was, and potentially still is, a drug for which there is no clear clinical evidence to suggest efficacy for anything. Tips of promise have never ever translated into real results.
How it became thought about by some as the cure-all for cancer, is another tale completely, and one well worth following. In a 2017 expose by Snopes, capably assisted by the Anticancer Fund (ACF), gcmaf was finally exposed. In the post, its developer and primary advocate, Dr. Nobuto Yamamoto. Was revealed to be guilty of falsifying clinical trials in a collective decades-long effort to offer the lie of gcmaf.
The seriousness and ramifications of Yamamoto’s fraud have prevalent implications for the medical neighborhood, its publications, and the procedures it depends on to confirm brand-new medicines. It has highlighted how a once-respected member of the medical community can go rogue, utilizing the system’s “fail-safes” against it. The gcmaf saga should not be forgotten. It acts as a permanent tip of unaddressed industry loopholes, most of which remain in place.
The result of publishers not getting rid of problematic research study results in yet more documents, based upon the theories promoted in the original disproven research. Here is a traditional example, where 2 of Yamamoto’s papers on gcmaf have been referenced by researchers, in a recent paper entitled “Prospective role of gcmaf in reducing the severity of COVID-19-induced immune reactions: Lesson gained from HIV”.
Two concerns to the publications involved. Why have you refused to pull back Yamamoto’s incorrect papers and where is the peer evaluation process that would determine the research study in the paper referenced above to be flawed? Allowing incorrect and flawed research studies to continue endangers the general public.
You can discover the total Snopes Article here. Entitled, “How a Retired Scientist’s Questionable ‘Institute’ Persuaded the Internet That Cancer Was Treated”, it makes for fascinating reading and we advise it as a case study in professionally perpetrated pharmaceutical deceptiveness. Yamamoto had taken pleasure in a long and recognized career till gcmaf, making the inspiration for the fraud that much more difficult to determine, and specialists remain divided on his real motivation.
In November of 2009, Yamamoto effectively sold his patents for gcmaf and associated intellectual property to an Israeli biopharmaceutical business, Efranat Macrophage. The company, after initially welcoming Yamamoto, gradually distanced itself from him, rebranding gcmaf as EFF-022 and reaching altering the drug’s name mid-trial.
While the medical neighborhood gradually turned their backs on gcmaf, the alternate health and conspiracy areas of the internet were far from done with their new darling, having actually seen the marketing and sales capacity for this brand-new “wonder” treatment. (7 )
” Cancer treated for good?”– GcMAF and the miracle cure
As an organisation devoted to beating cancer, we have a deep-rooted interest in any brand-new research developments that could lead to brand-new, more effective treatments for the illness.
So when we got an enquiry from a supporter about an article entitled “Cancer treated for good” by Costs Sardi and Timothy Hubbell * we were captivated. The post discuss research by Nobuto Yamamoto in the US, looking at a protein called GcMAF (aka gcmaf). His published studies appear to reveal that injections of very small amounts of GcMAF can “cure” individuals with breast, bowel and prostate cancer.
According to the short article, “It works 100% of the time to remove cancer totally, and cancer does not recur even years later on.” Could this be the so-called ‘remedy for cancer’ that we’ve been looking for all these years?
Sadly– just like so many things in life– if it sounds too great to be real it probably is. Major concerns are now being raised about GcMAF (for instance, this investigation by the BBC) and the companies that sell it, and it is not licensed in the UK to treat any disease.
Let’s check out a bit further.
What’s the idea behind it?
Dr Yamamoto studies the body immune system– the extremely complex network of cells that helps to keep us healthy. The cells of the body immune system– white blood cells– fight bacterial and viral infections because they can identify and attack these ‘foreign’ intruders. But they’re not so proficient at taking on cancer, given that tumours grow from our own cells and have smart systems to ‘mask’ them from immune attack.
Macrophages (significance “big eaters” in Greek) are an essential type of white blood cell. They patrol the body, consuming foreign intruders and dead cells. They likewise assist to notify other immune cells to the presence of infections.
Macrophages can be stirred into action by a small sugar-coated protein (glycoprotein) called GcMAF, short for Gc Macrophage Triggering Aspect, which is produced by the body. However it’s thought that the production of GcMAF is obstructed by an enzyme called Nagalase (alpha-N-acetylgalactosaminidase), produced by numerous cancers. This is among the mechanisms that assists tumours evade the immune system.
Yamamoto’s theory is that injecting cancer patients with GcMAF need to trigger their macrophages to combat the cancer. He evaluated it back in 1997 in a paper published in the journal Cancer Research study, revealing that injecting GcMAF into mice transplanted with cancer cells could enhance their survival from around 16 days to around 35.
But the treatment did not ‘cure’ the cancer, as the cancer cells continued to increase, ultimately killing the animals.
Nevertheless, there are concerns about the science underpinning the idea that GcMAF can deal with cancer. For instance, other scientists have actually discovered no differences in the levels of GcMAF between cancer patients and healthy individuals– and the levels they do discover are far higher than the very small doses proposed to work by Yamamoto. It’s difficult to see precisely how this finding fits with the idea of how the treatment is expected to work, and it does not support the use of GcMAF as a treatment for cancer.
Fast-forward a few years, to the publication of 3 papers detailing the outcomes of clinical trials of GcMAF carried out by Yamamoto, evaluating the treatment on patients with breast, bowel and prostate cancer.
Note: The breast cancer paper has actually now been pulled back, due to various concerns with the work. Find out more on the retractionwatch blog. The bowel cancer paper has actually also now been pulled back. This letter details some of the concerns about the work.
The results seem surprising– all the clients on the trials are ‘treated’ of cancer. Undoubtedly this is an incredible development?
Put candidly, no it isn’t. There are substantial scientific problems with the trials. For a start, all the studies are extremely little, including less than twenty clients in each– instead of the thousands required to make the sort of claims mentioned above.
Next, all the patients included had actually received standard treatment for their cancer, including surgery, chemotherapy and/or radiotherapy. This is a rather unconventional style for a trial of this kind, because it makes it really hard to inform if any successes are due to the brand-new drug, or the more traditional treatments.
On top of this, the scientists didn’t in fact monitor the development of tumours in the clients, and supply no clinical info about them. Rather they decide to determine levels of Nagalase in the blood, rather than looking at any basic recognized markers for cancer.
For example, when it comes to the breast cancer patients, there is no detail about their “TNM” (tumour, node, metastasis) status. This is a standard measure of how far a patient’s cancer has spread, and is used to compute the possibility that it will return.
Furthermore, the researchers didn’t do any tests to show that injected GcMAF was in fact triggering macrophages in the clients’ blood, or even operating in the manner in which they expect. There is no information about levels of cytokines– the proteins produced by immune cells when they are triggered– or analysis of the clients’ immune cells.
Perhaps most significantly, there are no controls– untreated patients for comparison– and the studies only followed the patients for a few years. We have no chance of informing whether their cancers were growing once again, or had been effectively dealt with, and whether this was because of GcMAF or the other treatment they had received.
Considered that 80 per cent of all females with breast cancer endure for at least 5 years, an unchecked study revealing that 16 ladies of unidentified TNM status survive for at least 4 years is no fantastic shakes, clinically speaking.
Another small research study of 20 clients with a range of cancers, released in 2013, has similar problems. It’s not a controlled trial, and the researchers just determine nagalase levels as a sign of whether the treatment is ‘working’, and provide extremely little tough scientific data (such as scans or other recognised tests) about the patients’ actual tumours. For instance, in one worrying case, although the scientists revealed that an ovarian cancer patient’s nagalase levels had actually decreased, the levels of another marker– CA125, which is produced by ovarian cancer cells– had actually increased. Yet this is classed as an “improvement” in the paper, without any other supporting details. Overall, this study is also a long way from being persuading evidence that the treatment is effective.
Another informing point is the kind of journal in which the research was published. If this research was truly cutting-edge, and pointed the way to a cure for cancer, then the research study would likely be discovered in top-tier ‘high-impact’ medical journals like The Lancet, The New England Journal of Medication or the Journal of the American Medical Association.
And finally, virtually all the recommendations in the documents are to other papers released by Yamamoto and his group. If GcMAF was indeed an appealing candidate for a successful cancer treatment, you ‘d anticipate plenty of other research study to reveal the exact same thing. Researchers are normally quick to find promising, emerging fields of research study and follow suit.
The poor quality of clinical documents supporting gcmaf is gone over here on the Scholarly Open Gain access to blog site.
Although this specific technique isn’t all it’s hyped as much as be, harnessing the power of immune system could be a very potent method to treat cancer.
And many Cancer Research UK-funded researchers are likewise working in this field. For example, Professor Fran Balkwill and her group are working on ways to fool macrophages and other immune cells into assaulting cancer cells.
In 2014, researchers in Israel started a small-scale early-stage medical trial looking at the dosage and security of gcmaf in cancer clients. (8 ).
Dr Yamamoto specifies gcmaf does not have negative effects. Our experiences concur: gcmaf has actually revealed no side effects of its own. That’s not unexpected– your body anticipates to have it.
However your rebuilt immune system might sometimes give you small side effects, but bigger negative effects with late phases of cancer, and periodically serious effects with autism, HIV and ME/CFS, as infections resist versus the rebuilt body immune system’s attack.
People’s responses to a rebuilt body immune system are extremely different– from no, which is common, to serious in a minority of cases.
Inside two hours gcmaf will start to impact your body immune system, and (if your body immune system is at least partly active) a shot of 0.1 ml or more may cause exhaustion which usually lasts 3-4 hours. You may feel much better than usual for the very first 2-3 weeks as the immune system awakens.
Gcmaf is a protein that your body must have made by itself, and there is a small opportunity (under 0.1%) you might have an allergy, normally within the very first 2 hours. If in doubt start with a 0.05 ml dosage, then 0.1 after 12 hours. If you do have a reaction, it can be treated with anti-histamine tablets, which can typically be purchased from a chemist without prescription (hay fever is an allergy).
We have actually seen favorable, however not yet negative autoimmune reactions.
Other small side effects may include cytokine activity (with accompanying fatigue and minor weight reduction, no such reports yet), histamine release (with potentially a headache) and the symptoms of a fever (3.5 hours of hot flushes) as the body immune system goes to work.
The majority of never ever notice anything more than an improving sense of well being. (9 ).
Other crucial points
Triggering macrophages with High Dose GcMAF is a fundamental part of any treatment program which can be used alone or in mix with many other treatments.
GcMAF works particularly well in synergy with targeted treatments which don’t hurt the immune system. Examples of targeted treatments include hormone treatments, monoclonal antibody drugs, small-molecule drugs, signal transduction inhibitors (HER2 inhibitors, BRAF inhibitors, EGFR inhibitors), angiogenesis inhibitors, immunotherapy drugs (such as drugs that target CTLA-4 protein).
2nd Generation GcMAF has the advantage of having no side effects so treatment must be continued as long as essential while illness is present. This is a significant advantage over lots of standard treatments which have cumulative toxicity that restricts their use.
GcMAF never ever stops working and will continue to activate macrophages while treatment is continued, either by GcMAF injections and/or oral administration of Colostrum GcMAF. (10 ).